Italian researchers used an animal model of multiple sclerosis to investigate the efficacy of cannabis extracts on motor symptoms. They found that treating with a THC-rich extract over time “resulted in a significant reduction of neurological deficits,” that treatment with CBD affected only the relapse phase, and that combined THC-CBD treatment was ineffective. They suggest further investigation on each cannabinoid’s action but conclude that cannabis extracts have potential for managing MS.

Another Italian research team reviewed studies on cannabinoid receptors in the lower urinary tract and their role in controlling urinary tract function, including the treatment of bladder dysfunction resulting from MS, finding that systemic cannabinoids may be clinically useful.
British scientists reviewing the clinical data on treating MS with cannabinoids note patient reports of symptomatic relief are confirmed by data showing cannabinoids improve muscle stiffness and spasms, neuropathic pain, and sleep and bladder disturbance. They note new evidence suggests that cannabinoids may affect “fundamental processes” in the progression of MS. They suggest “cannabinoids may have a longer term role in reducing disability and progression in MS.”

Scientists who examined brain samples of deceased MS patients for CB1 and CB2 receptors, as well as an enzyme related to the synthesis of endocannabinoids, found differences in receptor concentration that correlated to MS damage. Their findings support animal studies that suggest the endocannabinoid system has a role in MS progression and cellular response to injuries from the disease.

Buccellato E, et al. 2011. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis. J Ethnopharmacol. 133(3):1033-8.
Zajicek JP, Apostu VI. 2011. Role of cannabinoids in multiple sclerosis. CNS Drugs. 1;25(3):187-201.
Zhang H,et al. 2011. Cannabinoid Receptor and N-acyl Phosphatidylethanolamine Phospholipase D-Evidence for Altered Expression in Multiple Sclerosis. Brain Pathol.
Ruggieri MR Sr. 2011. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. (202):425-51.

Leave a Reply

Your email address will not be published. Required fields are marked *